{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:46:40Z","timestamp":1769582800775,"version":"3.49.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1097\/inf.0000000000001339","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T08:49:51Z","timestamp":1474015791000},"page":"e1-e13","source":"Crossref","is-referenced-by-count":15,"title":["Safety, Efficacy, and Exposure\u2013Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis"],"prefix":"10.1097","volume":"36","author":[{"given":"Judith M.","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Macias-Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mudry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Conte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean L.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Rita","family":"Capparella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalal A.","family":"Aram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210202","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2110-5820-2-6","article-title":"Invasive fungal disease in PICU: epidemiology and risk factors.","volume":"2","author":"Brissaud","year":"2012","journal-title":"Ann Intensive Care"},{"key":"R2-2-20210202","first-page":"175","article-title":"Lessons about the pathogenesis and management of aspergillosis from studies in chronic granulomatous disease.","volume":"118","author":"Gallin","year":"2007","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"R3-2-20210202","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-199809000-00004","article-title":"Aspergillus nidulans infection in chronic granulomatous disease.","volume":"77","author":"Segal","year":"1998","journal-title":"Medicine (Baltimore"},{"key":"R4-2-20210202","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.1542\/peds.2007-2117","article-title":"Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases.","volume":"121","author":"Burgos","year":"2008","journal-title":"Pediatrics"},{"key":"R5-2-20210202","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R6-2-20210202","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.earlhumdev.2011.01.017","article-title":"Invasive candidiasis in neonates and children.","volume":"87(suppl 1)","author":"Roilides","year":"2011","journal-title":"Early Hum Dev"},{"key":"R7-2-20210202","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1513\/pats.200907-075AL","article-title":"Coping with Candida infections.","volume":"7","author":"Evans","year":"2010","journal-title":"Proc Am Thorac Soc"},{"key":"R8-2-20210202","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00431-007-0527-7","article-title":"Fungal infections in primary immunodeficiencies.","volume":"166","author":"Antachopoulos","year":"2007","journal-title":"Eur J Pediatr"},{"key":"R9-2-20210202","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R10-2-20210202","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children.","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R11-2-20210202","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jac\/dkr517","article-title":"Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.","volume":"67","author":"Soler-Palac\u00edn","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R12-2-20210202","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole.","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R13-2-20210202","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.clpt.6100482","article-title":"Pharmacokinetics\/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations.","volume":"84","author":"Myrand","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R14-2-20210202","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/322653","article-title":"A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.","volume":"33","author":"Ally","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R15-2-20210202","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"R16-2-20210202","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"R17-2-20210202","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1128\/AAC.00896-10","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-2-20210202","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/MPH.0b013e3182331bc7","article-title":"Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.","volume":"33","author":"Mandhaniya","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"R19-2-20210202","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200203000-00015","article-title":"Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.","volume":"21","author":"Walsh","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R20-2-20210202","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.1128\/AAC.00531-11","article-title":"Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.","volume":"55","author":"Driscoll","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-2-20210202","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-2-20210202","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial.","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"R23-2-20210202","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group.","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R24-2-20210202","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.02808-13","article-title":"Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.","volume":"58","author":"Liu","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-2-20210202","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-2-20210202","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbmt.2015.11.011","article-title":"Genotype-directed dosing leads to optimized voriconazole levels in pediatric patients receiving hematopoietic stem cell transplantation.","volume":"22","author":"Teusink","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R27-2-20210202","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1365-2125.2003.02000.x","article-title":"Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.","volume":"56(suppl 1)","author":"Wood","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R28-2-20210202","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2334-13-105","article-title":"Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.","volume":"13","author":"Chu","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R29-2-20210202","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-2-20210202","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1128\/AAC.02809-13","article-title":"Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.","volume":"58","author":"Liu","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-2-20210202","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1086\/374248","article-title":"Safety of voriconazole and dose individualization.","volume":"36","author":"Lutsar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R32-2-20210202","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R33-2-20210202","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1439-0507.2012.02186.x","article-title":"Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.","volume":"55","author":"Racil","year":"2012","journal-title":"Mycoses"},{"key":"R34-2-20210202","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities.","volume":"46","author":"Tan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R35-2-20210202","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","article-title":"Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.","volume":"40","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R36-2-20210202","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R37-2-20210202","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12185-009-0296-3","article-title":"Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders.","volume":"89","author":"Ueda","year":"2009","journal-title":"Int J Hematol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:12:26Z","timestamp":1620954746000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201701000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001339","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}